RxDoctor Payments Data

Joanie Hope, MD

Gynecologic Oncology · Anchorage, AKNPI 1265651053

Payments from drug & device makers

$1,383,900in general payments, 2019–2025

Across 177 payments — averaging $7818.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$760K
  • Tesaro, Inc.$620K
  • Intuitive Surgical$3K
  • AstraZeneca$634
  • Astellas Pharma US Inc$199
  • Seagen Inc.$190
  • plus $327 from 7 others

What the payments were for

  • Travel & lodging$1,35034%
  • Food & beverage$1,87747%
  • Education$2957%
  • Gifts$49712%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$132,710
Medicare patients
191
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib41$306,589
ZejulaNiraparib Tosylate11$199,600
IbrancePalbociclib11$173,332
EliquisApixaban47$28,495
Omeprazole49$1,528
Letrozole33$544
Ondansetron OdtOndansetron24$298
Dexamethasone52$237
Olanzapine25$232
Prochlorperazine Maleate19$177
Oxycodone Hcl41$149
Gabapentin17$74
Ondansetron Hcl15$59
Lisinopril21$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$634$306,58941 claims
GSKZejula$759,908$199,60011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecologic oncology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other gynecologic oncology in Anchorage

Where these figures come from

Is this you, or does something look wrong? →